Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Christopher M. Starr Sells 16,800 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) Director Christopher M. Starr sold 16,800 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the director directly owned 5,173 shares in the company, valued at approximately $206,920. This trade represents a 76.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Monopar Therapeutics Stock Down 1.6%

Monopar Therapeutics stock traded down $0.77 during mid-day trading on Friday, hitting $46.48. 30,457 shares of the company's stock traded hands, compared to its average volume of 363,996. The firm has a 50 day moving average price of $35.86 and a 200 day moving average price of $36.31. The company has a market cap of $284.46 million, a PE ratio of -13.36 and a beta of 1.01. Monopar Therapeutics Inc. has a one year low of $1.72 and a one year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.27. On average, analysts expect that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

MNPR has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald initiated coverage on shares of Monopar Therapeutics in a research report on Monday, July 7th. They issued an "overweight" rating and a $74.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Finally, Chardan Capital began coverage on shares of Monopar Therapeutics in a research note on Monday, June 23rd. They issued a "buy" rating and a $60.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $60.00.

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently added to or reduced their stakes in MNPR. AlphaQuest LLC bought a new position in Monopar Therapeutics in the first quarter valued at approximately $44,000. JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics in the 4th quarter worth about $45,000. Gerber LLC bought a new position in shares of Monopar Therapeutics during the 1st quarter valued at approximately $204,000. OMERS ADMINISTRATION Corp bought a new stake in Monopar Therapeutics in the 1st quarter valued at about $328,000. Finally, Jane Street Group LLC bought a new position in Monopar Therapeutics in the 1st quarter worth approximately $377,000. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.